Alper KARALÖK, Reyhan ÖCALAN, Ahmet Taner TURAN, Levent ŞİRVAN, Tolga TAŞÇI, Tayfun GÜNGÖR, Murat ÖZ, Mehmet Mutlu MEYDANLI

Vanishing endometrial carcinoma in hysterectomy specimens: probable implications for fertility sparing management

Background/aim: The vanishing cancer phenomenon was first reported in radical prostatectomy specimens in the absence of neoadjuvant treatment. Reported cases are mostly well-differentiated and low-volume tumors. A similar entity was described for hysterectomy specimens of patients with biopsy proven endometrial cancer (EC). In this study, we discuss the probable reasons for vanishing EC and long-term follow-up results of EC patients without residual tumors in hysterectomy specimens. Materials and methods: This study was carried at two institutions in Ankara, Turkey, in a retrospective design. The computerized databases of both institutions were searched for endometrioid type EC patients whose final pathological specimens failed to show any residual tumor. Results: We evaluated 38 endometrial biopsy confirmed EC patients with no residual tumor detected in the hysterectomy specimens among a total of 224 women (17%) with the disease confined to the endometrium. During the follow-up period, no recurrences were noted among the patients. Conclusion: It can be suggested that premenopausal women with FIGO grade 1 endometrioid type EC with MRI proven absent myometrial invasion would have a significant probability of having no residual tumor after endometrial biopsy without any further medical treatment.

PDF

___

1. Goldstein NS, Begin LR, Grody WW, Novak JM, Qian J, Bostwick DG. Minimal or no cancer in radical prostatectomy specimens. Report of 13 cases of the vanishing cancer phenomenon. Am J Surg Pathol 1995; 19: 1002-1009.
2. DiGiuseppe JA, Sauvageot J, Epstein JI. Increasing incidence of minimal residual cancer in radical prostatectomy specimens. Am J Surg Pathol 1997; 21: 174-178.
3. Bostwick DG, Bostwick KC. Vanishing prostate cancer in radical prostatectomy specimens: incidence and long-term follow-up in 38 cases. BJU Int 2004; 94: 57-58.
4. Cao D, Hafez M, Berg K, Murphy K, Epstein JI. Little or no residual prostate cancer at radical prostatectomy: vanishing cancer or switched specimen? A microsatellite analysis of specimen identity. Am J Surg Pathol 2005; 29: 467-473.
5. Herkommer K, Kuefer R, Gschwend JE, Hautmann RE, Volkmer BG. Pathological T0 prostate cancer without neoadjuvant therapy: clinical presentation and follow-up. Eur Urol 2004; 45: 36-41.
6. Ahmed QF, Gattoc L, Al-Wahab Z, Abdulfatah E, Ruterbusch JJ, Cote M, Bandyopadhyay S, Morris RT, Ali-Fehmi R. Vanishing endometrial cancer in hysterectomy specimens: a myth or a fact. Am J Surg Pathol 2015; 39: 221-226.
7. Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, Chi DS, Soslow RA, Abu-Rustum NR. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009; 113: 105-108.
8. Dube V, Macdonald D, Allingham-Hawkins DJ, Kamel-Reid S, Colgan TJ. Vanishing endometrial carcinoma. Int J Gynecol Pathol 2007; 26: 271-277.
9. Aquino-Parsons C, Lim P, Wong F, Mildenberger M. Papillary serous and clear cell carcinoma limited to endometrial curettings in FIGO stage 1a and 1b endometrial adenocarcinoma: treatment implications. Gynecol Oncol 1998; 71: 83-86.
10. Rodolakis A, Biliatis I, Morice P, Reed N, Mangler M, Kesic V, Denschlag D. European Society of Gynecological Oncology Task Force for Fertility Preservation: Clinical Recommendations for Fertility-Sparing Management in Young Endometrial Cancer Patients. Int J Gynecol Cancer. 2015; 25: 1258-1265.
11. Frei KA, Kinkel K, Bonel HM, Lu Y, Zaloudek C, Hricak H. Prediction of deep myometrial invasion in patients with endometrial cancer: clinical utility of contrast-enhanced MR imaging - a meta-analysis and Bayesian analysis. Radiology 2000; 216: 444-449.
12. Rosenberg P, Blom R, Hogberg T, Simonsen E. Death rate and recurrence pattern among 841 clinical stage I endometrial cancer patients with special reference to uterine papillary serous carcinoma. Gynecol Oncol 1993; 51: 311-315.
13. Elit L, Kwon J, Bentley J, Trim K, Ackerman I, Carey M. Optimal management for surgically Stage 1 serous cancer of the uterus. Gynecol Oncol 2004; 92: 240-246.